GlaxoSmithKline Pharmaceuticals Limited (GSK India) has announced that it received a Decree dated 6th May 2025 from the Court of Small Causes, Bombay, on 2nd November 2025. The Decree pertains to Mesne Profit for office premises formerly used by Burroughs Wellcome (India) Limited, prior to its merger with GSK India. The total demand specified in the Decree amounts to ₹38.06 crores. This includes ₹87.09 lakhs related to Mesne Profit and ₹37.19 crores as simple interest at a rate of 9% from June 2001. GSK India stated that the Company is currently evaluating the Decree and will take appropriate actions, including filing an appeal, to mitigate any potential impacts. The company mentioned that this matter is over 24 years old and that due to the lack of immediate records, the intimation was delayed.